Product Code: TMRGL374
The report provides revenue of the global non-invasive prenatal testing market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-invasive prenatal testing market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the non-invasive prenatal testing market.
The report delves into the competitive landscape of the global non-invasive prenatal testing market. Key players operating in the global non-invasive prenatal testing market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global non-invasive prenatal testing market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Non-invasive Prenatal Testing Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Test Type Definition
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Non-invasive Prenatal Testing Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
- 5.1. Key Industry Evolution/Developments
- 5.2. Cost Comparison Analysis
- 5.3. Advancement in NIPT
- 5.4. Covid 19 Impact Analysis
6. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Test Type
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Test Type, 2017-2031
- 6.3.1. Materni21
- 6.3.2. Harmony
- 6.3.3. Panorama
- 6.3.4. Verifi
- 6.3.5. NIFTY
- 6.3.6. Others
- 6.4. Market Attractiveness Analysis, by Test Type
7. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Application
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Application, 2017-2031
- 7.3.1. Trisomy
- 7.3.2. Micro-deletions Symptoms
- 7.3.3. Others
- 7.4. Market Attractiveness Analysis, by Application
8. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Technology
- 8.1. Introduction & Definition
- 8.2. Key Findings / Developments
- 8.3. Market Value Forecast, by Technology, 2017-2031
- 8.3.1. NGS
- 8.3.2. WGS
- 8.3.3. Others
- 8.4. Market Attractiveness Analysis, by Technology
9. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by End-user
- 9.1. Introduction & Definition
- 9.2. Key Findings / Developments
- 9.3. Market Value Forecast, by End-user, 2017-2031
- 9.3.1. Hospitals
- 9.3.2. Diagnostic Laboratories
- 9.3.3. Others
- 9.4. Market Attractiveness Analysis, by End-user
10. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Region
- 10.1. Key Findings
- 10.2. Market Value Forecast, by Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Market Attractiveness Analysis, by Region
11. North America Non-invasive Prenatal Testing Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Test Type, 2017-2031
- 11.2.1. Materni21
- 11.2.2. Harmony
- 11.2.3. Panorama
- 11.2.4. Verifi
- 11.2.5. NIFTY
- 11.2.6. Others
- 11.3. Market Value Forecast, by Application, 2017-2031
- 11.3.1. Trisomy
- 11.3.2. Micro-deletions Symptoms
- 11.3.3. Others
- 11.4. Market Value Forecast, by Technology, 2017-2031
- 11.4.1. NGS
- 11.4.2. WGS
- 11.4.3. Others
- 11.5. Market Value Forecast, by End-user, 2017-2031
- 11.5.1. Hospitals
- 11.5.2. Diagnostic Laboratories
- 11.5.3. Others
- 11.6. Market Value Forecast, by Country, 2017-2031
- 11.6.1. U.S.
- 11.6.2. Canada
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Test Type
- 11.7.2. By Application
- 11.7.3. By Technology
- 11.7.4. By End-user
- 11.7.5. By Country
12. Europe Non-invasive Prenatal Testing Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Test Type, 2017-2031
- 12.2.1. Materni21
- 12.2.2. Harmony
- 12.2.3. Panorama
- 12.2.4. Verifi
- 12.2.5. NIFTY
- 12.2.6. Others
- 12.3. Market Value Forecast, by Application, 2017-2031
- 12.3.1. Trisomy
- 12.3.2. Micro-deletions Symptoms
- 12.3.3. Others
- 12.4. Market Value Forecast, by Technology, 2017-2031
- 12.4.1. NGS
- 12.4.2. WGS
- 12.4.3. Others
- 12.5. Market Value Forecast, by End-user, 2017-2031
- 12.5.1. Hospitals
- 12.5.2. Diagnostic Laboratories
- 12.5.3. Others
- 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Spain
- 12.6.5. Italy
- 12.6.6. Rest of Europe
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Test Type
- 12.7.2. By Application
- 12.7.3. By Technology
- 12.7.4. By End-user
- 12.7.5. By Country/Sub-region
13. Asia Pacific Non-invasive Prenatal Testing Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Test Type, 2017-2031
- 13.2.1. Materni21
- 13.2.2. Harmony
- 13.2.3. Panorama
- 13.2.4. Verifi
- 13.2.5. NIFTY
- 13.2.6. Others
- 13.3. Market Value Forecast, by Application, 2017-2031
- 13.3.1. Trisomy
- 13.3.2. Micro-deletions Symptoms
- 13.3.3. Others
- 13.4. Market Value Forecast, by Technology, 2017-2031
- 13.4.1. NGS
- 13.4.2. WGS
- 13.4.3. Others
- 13.5. Market Value Forecast, by End-user, 2017-2031
- 13.5.1. Hospitals
- 13.5.2. Diagnostic Laboratories
- 13.5.3. Others
- 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Test Type
- 13.7.2. By Application
- 13.7.3. By Technology
- 13.7.4. By End-user
- 13.7.5. By Country/Sub-region
14. Latin America Non-invasive Prenatal Testing Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Test Type, 2017-2031
- 14.2.1. Materni21
- 14.2.2. Harmony
- 14.2.3. Panorama
- 14.2.4. Verifi
- 14.2.5. NIFTY
- 14.2.6. Others
- 14.3. Market Value Forecast, by Application, 2017-2031
- 14.3.1. Trisomy
- 14.3.2. Micro-deletions Symptoms
- 14.3.3. Others
- 14.4. Market Value Forecast, by Technology, 2017-2031
- 14.4.1. NGS
- 14.4.2. WGS
- 14.4.3. Others
- 14.5. Market Value Forecast, by End-user, 2017-2031
- 14.5.1. Hospitals
- 14.5.2. Diagnostic Laboratories
- 14.5.3. Others
- 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Test Type
- 14.7.2. By Application
- 14.7.3. By Technology
- 14.7.4. By End-user
- 14.7.5. By Country/Sub-region
15. Middle East & Africa Non-invasive Prenatal Testing Market Analysis and Forecast
- 15.1. Introduction
- 15.2. Market Value Forecast, by Test Type, 2017-2031
- 15.2.1. Materni21
- 15.2.2. Harmony
- 15.2.3. Panorama
- 15.2.4. Verifi
- 15.2.5. NIFTY
- 15.2.6. Others
- 15.3. Market Value Forecast, by Application, 2017-2031
- 15.3.1. Trisomy
- 15.3.2. Micro-deletions Symptoms
- 15.3.3. Others
- 15.4. Market Value Forecast, by Technology, 2017-2031
- 15.4.1. NGS
- 15.4.2. WGS
- 15.4.3. Others
- 15.5. Market Value Forecast, by End-user, 2017-2031
- 15.5.1. Hospitals
- 15.5.2. Diagnostic Laboratories
- 15.5.3. Others
- 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
- 15.7. Market Attractiveness Analysis
- 15.7.1. By Test Type
- 15.7.2. By Application
- 15.7.3. By Technology
- 15.7.4. By End-user
- 15.7.5. By Country/Sub-region
16. Competition Landscape
- 16.1. Market Player - Competition Matrix (by tier and size of companies)
- 16.2. Market Share Analysis, by Company, 2021
- 16.3. Company Profiles
- 16.3.1. Berry Genetics
- 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.1.2. Financial Analysis
- 16.3.1.3. Growth Strategies
- 16.3.1.4. SWOT Analysis
- 16.3.2. BGI
- 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.2.2. Financial Analysis
- 16.3.2.3. Growth Strategies
- 16.3.2.4. SWOT Analysis
- 16.3.3. Laboratory Corporation of America Holdings
- 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.3.2. Financial Analysis
- 16.3.3.3. Growth Strategies
- 16.3.3.4. SWOT Analysis
- 16.3.4. Agilent Technologies, Inc.
- 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.4.2. Financial Analysis
- 16.3.4.3. Growth Strategies
- 16.3.4.4. SWOT Analysis
- 16.3.5. Illumina, Inc.
- 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.5.2. Financial Analysis
- 16.3.5.3. Growth Strategies
- 16.3.5.4. SWOT Analysis
- 16.3.6. F. Hoffmann-La Roche Ltd.
- 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.6.2. Financial Analysis
- 16.3.6.3. Growth Strategies
- 16.3.6.4. SWOT Analysis
- 16.3.7. PerkinElmer, Inc.
- 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.7.2. Financial Analysis
- 16.3.7.3. Growth Strategies
- 16.3.7.4. SWOT Analysis
- 16.3.8. Eurofins LifeCodexx AG
- 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.8.2. Financial Analysis
- 16.3.8.3. Growth Strategies
- 16.3.8.4. SWOT Analysis
- 16.3.9. QIAGEN
- 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.9.2. Financial Analysis
- 16.3.9.3. Growth Strategies
- 16.3.9.4. SWOT Analysis
- 16.3.10. IGENOMIX
- 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.10.2. Financial Analysis
- 16.3.10.3. Growth Strategies
- 16.3.10.4. SWOT Analysis
- 16.3.11. Pacific Biosciences
- 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.11.2. Financial Analysis
- 16.3.11.3. Growth Strategies
- 16.3.11.4. SWOT Analysis
- 16.3.12. Natera, Inc.
- 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.12.2. Financial Analysis
- 16.3.12.3. Growth Strategies
- 16.3.12.4. SWOT Analysis